The gene therapy market is characterized by a healthy drug pipeline, with 10 approved molecules *Roots Analysis*

Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.

To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

The USD 14.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

§  Therapeutic approach

§  Gene augmentation

§  Oncolytic therapy

§  Immunotherapy

§  Others

§  Type of gene therapy

§  Ex vivo

§  In vivo

§  Type of vector used

§  Adeno associated virus

§  Adenovirus

§  Herpes simplex virus

§  Lentivirus

§  Plasmid DNA

§  Retrovirus

§  Others

§  Key therapeutic areas

§  Autoimmune disorders

§  Cardiovascular diseases

§  Dermatological disorders

§  Genetic disorders

§  Hematological disorders

§  Metabolic disorders

§  Muscle-related diseases

§  Oncological disorders

§  Ophthalmic diseases

§  Others

§  Route of administration

§  Intraarticular

§  Intracerebellar

§  Intradermal

§  Intramuscular

§  Intratumoral

§  Intravenous

§  Intravesical

§  Intravitreal

§  Subretinal

§  Others

§  Key geographical regions

§  North America

§  Europe

• Asia-Pacific 

The Gene Therapy Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

§  Abeona Therapeutics

§  Advantagene

§  Biogen

§  bluebird bio

§  Castle Creek Biosciences

§  CG Oncology

§  FerGene

§  Freeline Therapeutics

§  Gradalis

§  Helixmith

§  Inovio Pharmaceuticals

§  Kolon TissueGene

§  Krystal Biotech

§  Lysogene

§  Neurophth Therapeutics

§  OncoSec Immunotherapies

§  Orchard Therapeutics

§  Pfizer

§  Sangamo Therapeutics

§  Spark Therapeutics

§  uniQure Biopharma

§  VBL Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Gene Delivery Vectors

5. Regulatory Landscape and Reimbursement Scenario

6. Market Overview

7. Competitive Landscape 

8. Marketed Gene Therapies

9. Key Commercialization Strategies

10. Late Stage (Phase II/III and Above) Gene Therapies

11. Emerging Technologies

12. Key Therapeutics Areas

13. Patent Analysis

14. Mergers and Acquisitions

15. Funding and Investment Analysis

16. Clinical Trial Analysis

17. Cost Price Analysis

18. Big Pharma Players: Analysis of Gene Therapy Related Initiatives

19. Demand Analysis

20. Market Forecast and Opportunity Analysis

21. Vector Manufacturing

22. Case Study: Gene Therapy Supply Chain

23. Conclusion

24. Interview Transcripts

25. Appendix 1: Tabulated Data

26. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com